Trisalus life sciences, inc.TLSI.US Overview
TLSI Overall Performance
TLSI AI Analysis & Strategy
TLSI Recent Performance
1.31%
Trisalus life sciences, inc.
0.81%
Avg of Sector
-1.14%
S&P500
TLSI PowerScanner
TLSI Key Information
TLSI Valuation Metrics
TLSI Earnings Table
TLSI Profile
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.